Form 4: Artivion SVP Sells Shares for Tax, Receives New Grant

Artivion's SVP and General Counsel, Jean F. Holloway, sold shares to cover tax obligations from vested equity and received a new restricted stock grant.

Summary

• Jean F. Holloway, SVP and General Counsel of ARTIVION, INC. (AORT), reported transactions involving the company's common stock.
• On February 23, 2026, 3,079 shares of common stock were sold at $37.588 per share.
• On February 24, 2026, an additional 1,668 shares of common stock were sold at $35.693 per share.
• Both sales were non-discretionary 'sell to cover' transactions to satisfy tax withholding obligations upon the vesting of performance stock units and restricted stock units, respectively.
• On February 24, 2026, Holloway acquired 20,085 shares of restricted stock at a price of $0.
• These newly acquired restricted shares will vest 33 1/3% per year, starting on the first anniversary of the grant date, under the Equity and Cash Incentive Plan.
• Following these transactions, Holloway's direct beneficial ownership of common stock increased to 172,288 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While there were sales, they were non-discretionary for tax purposes. The significant new restricted stock grant indicates continued executive alignment and retention, which is a positive signal.

Positives

• The acquisition of 20,085 shares of restricted stock at $0 indicates a new equity grant to a key executive, aligning management's interests with shareholders.
• The vesting schedule of 33 1/3% per year over three years suggests a long-term retention strategy for the SVP, General Counsel.

Negatives

• A total of 4,747 shares were sold across two transactions to cover tax withholding obligations, reducing the executive's immediate direct holdings, though this was non-discretionary.

Future Outlook

The restricted stock grant indicates a future vesting schedule, with 33 1/3% of the 20,085 shares vesting annually starting one year from the grant date, aligning executive incentives with long-term company performance.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and expected practice for executives receiving equity compensation, as they are required to satisfy tax liabilities upon vesting. The grant of new restricted stock is a standard component of executive compensation packages in the medical technology industry, aiming to incentivize long-term performance and retention.

Comparison to Industry Standards

• The 'sell to cover' mechanism for tax withholding is a standard practice across publicly traded companies, including those in the medical device and biotechnology sectors, such as Medtronic or Edwards Lifesciences, where executives frequently receive equity as part of their compensation.
• Equity grants, particularly restricted stock units with multi-year vesting schedules, are a common incentive tool used by companies like Intuitive Surgical and Stryker to retain key talent and align executive interests with shareholder value creation over the long term.

Stakeholder Impact

• Shareholders: The new equity grant aligns the interests of a key executive with long-term shareholder value, potentially fostering sustained performance.
• Employees: The compensation structure for senior management, including equity grants, can influence overall company morale and talent retention strategies.

Next Steps

• The newly granted restricted stock will vest 33 1/3% per year beginning on the first anniversary of the grant date.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, specifically non-discretionary 'sell to cover' sales for tax purposes and a new restricted stock grant. These events are generally expected and do not typically indicate a significant shift in the company's fundamental outlook or warrant a change in investment recommendation based solely on this Form 4. The new grant is a positive for executive alignment, but the overall impact on stock price is likely neutral.

Keywords

Artivion, AORT, Form 4, Insider Trading, Restricted Stock Units, Performance Stock Units, Equity Grant, Executive Compensation, Stock Sale, Tax Withholding